{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-002935","form_type":"8-K","ticker":"WST","cik":"0000105770","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2022-02-17T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.288027+00:00","generated_at":"2026-06-27T06:53:05.271892+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"West Pharma reports record FY2021 sales $2.832B (+32%), guides FY2022 EPS $9.20-$9.35","bullets":["Q4 net sales $730.8M (+26%), organic +28.3%; full-year sales $2.832B (+31.9%), organic +29.4%.","Full-year reported diluted EPS $8.67 (+90%); adjusted diluted EPS $8.58 (+80%).","Proprietary Products segment Q4 sales $609.3M (+34.2%), driven by high-value product growth across all market units.","FY2022 guidance: net sales $3.050-$3.075B (~10% organic growth), reported EPS $9.20-$9.35, capex $380M.","Operating cash flow $584M (+23.6%), free cash flow $330.6M (+10.9%)."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-002935","json":"https://secwatch.observer/filing/0001628280-22-002935.json","markdown":"https://secwatch.observer/filing/0001628280-22-002935.md","text":"https://secwatch.observer/filing/0001628280-22-002935.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/105770/000162828022002935/0001628280-22-002935-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/105770/000162828022002935/wst-20220217.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T06:53:05.271892+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}